Supernus Pharmaceuticals (SUPN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.32
- Estimate
- $1.13
- Surprise
- +17.2%
- Revenue (period 2026-09-30)
- $226.8M
- Score at report (before → after)
- 6.6 → 6.8/10
Revenue source: xbrl.
How the report landed
Supernus Pharmaceuticals (SUPN) beat the $1.13 estimate with adjusted EPS of $1.32 — a large 17.2% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.6/10) to Sell at 6.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SUPN Buy (Wait) at 7.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +17.2% surprise compares with a +27.3% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%)
- RISK-OFF: SMALL-cap BUY_NOW needs quality>=8.5 or MoS>=50%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.64
- Entry target
- $27.81
- Price target
- $47.10
- Stop
- $25.86
- Upside to target
- +64.5%
- Reward-to-risk
- 5.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-20 — shown for context, not personalized investment advice.
SUPN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $5.89B
- P/E (fwd)
- 7.1
- 52-week range
- $25.92–$42.81
- Off 52-week high
- 33.1%
- RSI (14)
- 53
- Volume vs avg
- 0.43×
- Score today
- 7.0/10